Denali Therapeutics, Inc. (NASDAQ:DNLI) is one of the best oversold NASDAQ stocks to buy now. In a report released on July 7, Thomas Shrader from BTIG maintained a Buy rating on Denali Therapeutics, ...

Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Stock futures were mixed on Tuesday as investors looked ahead to the release of the Job Openings and Labor Turnover Survey (JOLTS) later in the day. Denali Therapeutics (NASDAQ:DNLI) shares ...

Stifel Nicolaus analyst Paul Matteis maintained a Hold rating on Denali Therapeutics (DNLI – Research Report) today and set a price target of $28.00. The company’s shares opened today at $30. ...

Denali Therapeutics' cutting-edge technology targets neurodegenerative diseases. Read why I DNLI stock is a Buy for investors who understand biotech risks.

Detailed price information for Denali Therapeutics Inc (DNLI-Q) from The Globe and Mail including charting and trades.

Below is Validea's guru fundamental report for DENALI THERAPEUTICS INC (DNLI). Of the 22 guru strategies we follow, DNLI rates highest using our Value Investor model based on the published ...